J&J (DIA3006)

A Randomized, Double-Blind, Placebo and  Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study Evaluate the Efficacy, Safety,  and Tolerability of JNJ-28431754  (Canagliflozin) Compared with Sitagliptin  and Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With  Inadequate Glycemic Control on Metformin Monotherapy.